scholarly journals Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects

2014 ◽  
Vol 16 (2) ◽  
Author(s):  
Shanshan Zhao ◽  
Rowan T Chlebowski ◽  
Garnet L Anderson ◽  
Lewis H Kuller ◽  
JoAnn E Manson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Randomized Trial ◽  
Hormone Therapy ◽  
Sex Hormone ◽  
Postmenopausal Hormone Therapy ◽  
Postmenopausal Hormone

scholarly journals Postmenopausal Hormone Therapy is Associated with in Situ Breast Cancer Risk

2012 ◽  
Vol 13 (8) ◽  
pp. 3917-3925 ◽  
Author(s):  
Xiao-Jian Ni ◽  
Tian-Song Xia ◽  
Ying-Chun Zhao ◽  
Jing-Jing Ma ◽  
Jie Zhao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Hormone Therapy ◽  
Postmenopausal Hormone Therapy ◽  
Postmenopausal Hormone ◽  
In Situ Breast Cancer

scholarly journals Postmenopausal hormone therapy and breast cancer risk: The multiethnic cohort

2005 ◽  
Vol 118 (5) ◽  
pp. 1285-1291 ◽  
Author(s):  
Sulggi Lee ◽  
Laurence Kolonel ◽  
Lynne Wilkens ◽  
Peggy Wan ◽  
Brian Henderson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Hormone Therapy ◽  
Postmenopausal Hormone Therapy ◽  
Postmenopausal Hormone ◽  
Multiethnic Cohort

scholarly journals Breast Cancer Risk by Breast Density, Menopause, and Postmenopausal Hormone Therapy Use

2010 ◽  
Vol 28 (24) ◽  
pp. 3830-3837 ◽  
Author(s):  
Karla Kerlikowske ◽  
Andrea J. Cook ◽  
Diana S.M. Buist ◽  
Steve R. Cummings ◽  
Celine Vachon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Hormone Therapy ◽  
Breast Density ◽  
Menopausal Status ◽  
Postmenopausal Hormone Therapy ◽  
Postmenopausal Hormone ◽  
Estrogen Plus Progestin ◽  
Very High

Purpose We determined whether the association between breast density and breast cancer risk and cancer severity differs according to menopausal status and postmenopausal hormone therapy (HT) use. Methods We collected data on 587,369 women who underwent 1,349,027 screening mammography examinations; 14,090 women were diagnosed with breast cancer. We calculated 5-year breast cancer risk from a survival model for subgroups of women classified by their Breast Imaging Reporting and Data System (BIRADS) breast density, age, menopausal status, and current HT use, assuming a body mass index of 25 kg/m2. Odds of advanced (ie, IIb, III, IV) versus early (ie, I, IIa) stage invasive cancer was calculated according to BIRADS density. Results Breast cancer risk was low among women with low density (BIRADS-1): women age 55 to 59 years, 5-year risk was 0.8% (95% CI, 0.6 to 0.9%) for non-HT users and 0.9% (95% CI, 0.7% to 1.1%) for estrogen and estrogen plus progestin users. Breast cancer risk was high among women with very high density (BIRADS-4), particularly estrogen plus progestin users: women age 55 to 59 years, 5-year risk was 2.4% (95% CI, 2.0% to 2.8%) for non-HT users, 3.0% (95% CI, 2.6% to 3.5%) for estrogen users, and 4.2% (95% CI, 3.7% to 4.6%) for estrogen plus progestin users. Advanced-stage breast cancer risk was increased 1.7-fold for postmenopausal HT users who had very high density (BIRADS-4) compared to those with average density (BIRADS-2). Conclusion Postmenopausal women with high breast density are at increased risk of breast cancer and should be aware of the added risk of taking HT, especially estrogen plus progestin.

Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin

Maturitas ◽  
2006 ◽  
Vol 55 (2) ◽  
pp. 103-115 ◽  
Author(s):  
Garnet L. Anderson ◽  
Rowan T. Chlebowski ◽  
Jacques E. Rossouw ◽  
Rebecca J. Rodabough ◽  
Anne McTiernan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Randomized Trial ◽  
Hormone Therapy ◽  
Women's Health ◽  
Women's Health Initiative ◽  
Health Initiative ◽  
Estrogen Plus Progestin ◽  
The Women’S Health Initiative
Sign in / Sign up

Export Citation Format

Share Document